Literature DB >> 21701147

Patients with psoriasis have a higher prevalence of parental cardiovascular disease.

Paolo Gisondi1, Camilla Dalle Vedove, Giampiero Girolomoni.   

Abstract

BACKGROUND: Parental history of cardiovascular disease (CVD) is an independent risk factor for offspring CVD. Patients with chronic plaque psoriasis have an intermediate risk of developing CVD.
OBJECTIVE: To investigate the prevalence of parental history of CVD in patients with psoriasis.
METHOD: A cross-sectional study on 236 adult patients with chronic plaque psoriasis and 246 controls was performed. Parental history of myocardial infarction and/or stroke was investigated by using a structured questionnaire. The accuracy of the self-reported information was confirmed by the hospital registry.
RESULTS: A positive parental history of maternal myocardial infarction was observed in 28/236 cases compared to 16/246 controls (11.8 vs. 6.5%; p = 0.04). A positive parental history of premature maternal myocardial infarction (i.e. <65 years) was observed in 16/236 cases compared to 3/246 controls (6.8 vs. 1.2%; p = 0.01). Moreover, a positive parental history of paternal stroke was observed in 25/236 cases compared to 14/246 controls (10.5 vs. 5.6%; p = 0.04). A positive parental history of psoriasis was higher in cases than in controls (35 vs. 2%; p < 0.001).
CONCLUSIONS: Parental history of CVD could also be investigated in patients with psoriasis for a more comprehensive estimation of their cardiovascular risk.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2011        PMID: 21701147     DOI: 10.1159/000328397

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  2 in total

1.  Hypovitaminosis D is Associated with Psoriasis: A Systematic Review and Meta-Analysis.

Authors:  Siwadon Pitukweerakul; Subhanudh Thavaraputta; Sittichoke Prachuapthunyachart; Rudruidee Karnchanasorn
Journal:  Kans J Med       Date:  2019-11-25

Review 2.  Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis.

Authors:  V Di Lernia; F Bardazzi
Journal:  Drug Des Devel Ther       Date:  2016-01-29       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.